Eintrag weiter verarbeiten
Myeloproliferative Neoplasms: New Translational Therapies
Gespeichert in:
| Zeitschriftentitel: | Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
|---|---|
| Personen und Körperschaften: | , |
| In: | Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 77, 2010, 6, S. 667-683 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Mascarenhas, John Hoffman, Ronald Mascarenhas, John Hoffman, Ronald |
|---|---|
| author |
Mascarenhas, John Hoffman, Ronald |
| spellingShingle |
Mascarenhas, John Hoffman, Ronald Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine Myeloproliferative Neoplasms: New Translational Therapies General Medicine |
| author_sort |
mascarenhas, john |
| spelling |
Mascarenhas, John Hoffman, Ronald 0027-2507 1931-7581 Wiley General Medicine http://dx.doi.org/10.1002/msj.20225 <jats:title>Abstract</jats:title><jats:p>The myeloproliferative neoplasms represent a diverse group of hematologic malignancies that have been the subject of intense investigation over the last decade. Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. Investigators remain optimistic that new information about the genetic and cellular origins gained from the efforts of numerous laboratories will ultimately translate in to the identification of new drug targets and more effective therapies. We hypothesize that ultimately, the use of combinations of drugs including chromatin modifying agents, immunomodulatory agents, anti‐apoptotic agents, cellular therapies and monoclonal antibodies will be required to effectively treat patients with myeloproliferative neoplasms. <jats:bold><jats:italic>Mt Sinai J Med 77:667–683, 2010.</jats:italic></jats:bold> © <jats:italic>2010 Mount Sinai School of Medicine</jats:italic></jats:p> Myeloproliferative Neoplasms: New Translational Therapies Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
| doi_str_mv |
10.1002/msj.20225 |
| facet_avail |
Online |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9tc2ouMjAyMjU |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9tc2ouMjAyMjU |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2010 |
| imprint_str_mv |
Wiley, 2010 |
| issn |
0027-2507 1931-7581 |
| issn_str_mv |
0027-2507 1931-7581 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
mascarenhas2010myeloproliferativeneoplasmsnewtranslationaltherapies |
| publishDateSort |
2010 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
| source_id |
49 |
| title |
Myeloproliferative Neoplasms: New Translational Therapies |
| title_unstemmed |
Myeloproliferative Neoplasms: New Translational Therapies |
| title_full |
Myeloproliferative Neoplasms: New Translational Therapies |
| title_fullStr |
Myeloproliferative Neoplasms: New Translational Therapies |
| title_full_unstemmed |
Myeloproliferative Neoplasms: New Translational Therapies |
| title_short |
Myeloproliferative Neoplasms: New Translational Therapies |
| title_sort |
myeloproliferative neoplasms: new translational therapies |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1002/msj.20225 |
| publishDate |
2010 |
| physical |
667-683 |
| description |
<jats:title>Abstract</jats:title><jats:p>The myeloproliferative neoplasms represent a diverse group of hematologic malignancies that have been the subject of intense investigation over the last decade. Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. Investigators remain optimistic that new information about the genetic and cellular origins gained from the efforts of numerous laboratories will ultimately translate in to the identification of new drug targets and more effective therapies. We hypothesize that ultimately, the use of combinations of drugs including chromatin modifying agents, immunomodulatory agents, anti‐apoptotic agents, cellular therapies and monoclonal antibodies will be required to effectively treat patients with myeloproliferative neoplasms. <jats:bold><jats:italic>Mt Sinai J Med 77:667–683, 2010.</jats:italic></jats:bold> © <jats:italic>2010 Mount Sinai School of Medicine</jats:italic></jats:p> |
| container_issue |
6 |
| container_start_page |
667 |
| container_title |
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
| container_volume |
77 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339146513055746 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:43:29.423Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Myeloproliferative+Neoplasms%3A+New+Translational+Therapies&rft.date=2010-11-01&genre=article&issn=1931-7581&volume=77&issue=6&spage=667&epage=683&pages=667-683&jtitle=Mount+Sinai+Journal+of+Medicine%3A+A+Journal+of+Translational+and+Personalized+Medicine&atitle=Myeloproliferative+Neoplasms%3A+New+Translational+Therapies&aulast=Hoffman&aufirst=Ronald&rft_id=info%3Adoi%2F10.1002%2Fmsj.20225&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339146513055746 |
| author | Mascarenhas, John, Hoffman, Ronald |
| author_facet | Mascarenhas, John, Hoffman, Ronald, Mascarenhas, John, Hoffman, Ronald |
| author_sort | mascarenhas, john |
| container_issue | 6 |
| container_start_page | 667 |
| container_title | Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
| container_volume | 77 |
| description | <jats:title>Abstract</jats:title><jats:p>The myeloproliferative neoplasms represent a diverse group of hematologic malignancies that have been the subject of intense investigation over the last decade. Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. Investigators remain optimistic that new information about the genetic and cellular origins gained from the efforts of numerous laboratories will ultimately translate in to the identification of new drug targets and more effective therapies. We hypothesize that ultimately, the use of combinations of drugs including chromatin modifying agents, immunomodulatory agents, anti‐apoptotic agents, cellular therapies and monoclonal antibodies will be required to effectively treat patients with myeloproliferative neoplasms. <jats:bold><jats:italic>Mt Sinai J Med 77:667–683, 2010.</jats:italic></jats:bold> © <jats:italic>2010 Mount Sinai School of Medicine</jats:italic></jats:p> |
| doi_str_mv | 10.1002/msj.20225 |
| facet_avail | Online |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9tc2ouMjAyMjU |
| imprint | Wiley, 2010 |
| imprint_str_mv | Wiley, 2010 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-Ch1, DE-L229 |
| issn | 0027-2507, 1931-7581 |
| issn_str_mv | 0027-2507, 1931-7581 |
| language | English |
| last_indexed | 2024-03-01T15:43:29.423Z |
| match_str | mascarenhas2010myeloproliferativeneoplasmsnewtranslationaltherapies |
| mega_collection | Wiley (CrossRef) |
| physical | 667-683 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
| source_id | 49 |
| spelling | Mascarenhas, John Hoffman, Ronald 0027-2507 1931-7581 Wiley General Medicine http://dx.doi.org/10.1002/msj.20225 <jats:title>Abstract</jats:title><jats:p>The myeloproliferative neoplasms represent a diverse group of hematologic malignancies that have been the subject of intense investigation over the last decade. Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. Investigators remain optimistic that new information about the genetic and cellular origins gained from the efforts of numerous laboratories will ultimately translate in to the identification of new drug targets and more effective therapies. We hypothesize that ultimately, the use of combinations of drugs including chromatin modifying agents, immunomodulatory agents, anti‐apoptotic agents, cellular therapies and monoclonal antibodies will be required to effectively treat patients with myeloproliferative neoplasms. <jats:bold><jats:italic>Mt Sinai J Med 77:667–683, 2010.</jats:italic></jats:bold> © <jats:italic>2010 Mount Sinai School of Medicine</jats:italic></jats:p> Myeloproliferative Neoplasms: New Translational Therapies Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine |
| spellingShingle | Mascarenhas, John, Hoffman, Ronald, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, Myeloproliferative Neoplasms: New Translational Therapies, General Medicine |
| title | Myeloproliferative Neoplasms: New Translational Therapies |
| title_full | Myeloproliferative Neoplasms: New Translational Therapies |
| title_fullStr | Myeloproliferative Neoplasms: New Translational Therapies |
| title_full_unstemmed | Myeloproliferative Neoplasms: New Translational Therapies |
| title_short | Myeloproliferative Neoplasms: New Translational Therapies |
| title_sort | myeloproliferative neoplasms: new translational therapies |
| title_unstemmed | Myeloproliferative Neoplasms: New Translational Therapies |
| topic | General Medicine |
| url | http://dx.doi.org/10.1002/msj.20225 |